Overview

Pharmacogenetics of Doxazosin for Cocaine Dependence

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Doxazosin, an alpha 1-adrenergic receptor antagonist, may play an important role in cocaine addiction in humans. This study will evaluate to what extent the prospective screening for catecholamine related polymorphisms for alpha 1 NE receptor/transporter, COMT and DBH as main targets predict the treatment efficacy of doxazosin for cocaine-using behavior.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor College of Medicine
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cocaine
Doxazosin